Abstract

Acute leukemia of ambiguous lineage (ALAL) is a rare type of leukemia and represents an unmet clinical need. In fact, due to heterogeneity, substantial rarity and absence of clinical trials, there are no therapeutic guidelines available. We investigated the genetic basis of 10 cases of ALAL diagnosed at our centre from 2008 and 2020, through a targeted myeloid and lymphoid sequencing approach. We show that this rare group of acute leukemias is enriched in myeloid-gene mutations. In particular we found that RUNX1 mutations, which have been found double mutated in 40% of patients and tend to involve both alleles, are associated with an undifferentiated phenotype and with lineage ambiguity. Furthermore, because this feature is typical of acute myeloid leukemia with minimal differentiation, we believe that our data strengthen the idea that acute leukemia with ambiguous lineage, especially those with an undifferentiated phenotype, might be genetically more closer to acute myeloid leukemia rather than acute lymphoblastic leukemia. These data enrich the knowledge on the genetic basis of ALAL and could have clinical implications as an acute myeloid leukemia (AML) – oriented chemotherapeutic approach might be more appropriate.

Highlights

  • IntroductionAcute leukemia of ambiguous lineage is a group of rare leukaemia with mixed features of lymphoblastic and myeloid lineage, which represents

  • Attention must be paid in differential diagnosis between acute undifferentiated leukemia (AUL) and acute myeloid leukemia (AML) with minimal differentiation, which grossly corresponds to the previous M0 by the French–American–British (FAB) classification

  • In a subset of cases with RUNX1 double mutations, we explored the reads generated from DNA or RNA libraries spanning both positions in order to determine if mutations involved one allele or both alleles

Read more

Summary

Introduction

Acute leukemia of ambiguous lineage is a group of rare leukaemia with mixed features of lymphoblastic and myeloid lineage, which represents

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.